BioInvent (Q1 Review): Mid-Year Readouts Are Catalysts - Redeye

Redeye comments on BioInvent's Q1 report 2026, which was a transitional quarter with limited news since our Q4 review. The mid-year readouts from BI-1206 in the triplet study in NHL and from BI-1808 in T-cell lymphoma will drive the share and potentially position these assets for a deal.

Länk till analysen i sin helhet: https://www.redeye.se/research/1163183/bioinvent-q1-review-mid-year-readouts-are-catalysts?utm_source=finwire&utm_medium=RSS